99.1
|
Updated Company Investor Presentation - June 2015
|
Date: June 3, 2015
|
KAMADA LTD.
|
||
|
By:
|
/s/ Gil Efron | |
Gil Efron
|
|||
Chief Financial Officer
|
EXHIBIT NO.
|
DESCRIPTION
|
99.1
|
Updated Company Investor Presentation - June 2015
|
Product
|
Indication
|
Phase I
|
Phase II
|
Phase III
|
Market
|
Partners
|
Intravenous
AAT |
AAT Deficiency
|
|
U.S.:
|
|||
D1-AAT (IV)
|
Type 1 Diabetes*
|
|
U.S.:
|
|||
G1-AAT (IV)
|
GVHD*
|
|
|
U.S.:
|
||
L1-AAT (IV)
|
Lung transplant
|
|
|
U.S.:
|
||
Inhaled AAT
|
AAT Deficiency*
|
|
EU:
|
|||
B1-AAT (IH)
|
Bronchiectasis*
|
|
|
|
||
C1-AAT (IH)
|
Cystic Fibrosis*
|
|
|
|
||
KamRAB (IM)
|
Prophylaxis for
Rabies |
|
U.S.:
|
Lung
Function |
Least Squares Means (SEM)
(Changes at Week 50 from Baseline) |
P-Value*
(Changes at Week 50) |
Least Squares Means
(SEM) (overall treatment effect) |
P-Value*
(Overall Effect) |
||
AAT
(N= 84)
|
Placebo
(N= 81)
|
AAT
(N= 84)
|
Placebo
(N= 81)
|
|||
FEV1 (L)
|
-12mL
-0.01183
(0.02196) |
-62mL
-0.06216
(0.02036) |
0.0956
|
+15mL
0.01503
(0.01338) |
-27mL
-0.02718
(0.01322)
|
0.0268
|
FEV1 (% of
predicted) |
-0.1323
(0.6649)
|
-1.6205
(0.6140)
|
0.1032
|
0.5404
(0.4451)
|
-0.6273
(0.4425)
|
0.0658
|
FEV1/SVC
(%) |
0.6183
(0.5015)
|
-1.0723
(0.4455)
|
0.0132
|
0.6230
(0.3931)
|
-0.8715
(0.3804)
|
0.0074
|
ITT
|
N (%)
|
||
AAT
|
Placebo
|
||
Type/Category
|
N=85
|
N=83
|
|
Type I
|
16 (18.8%)
|
26 (31.3%)
|
0.0614
|
Type II
|
23 (27.1%)
|
12 (14.5%)
|
0.0444
|
Type III
|
34 (40.0%)
|
33 (39.8%)
|
0.9746
|
None
|
12 (14.1%)
|
12 (14.5%)
|
0.9498
|
Symptom
|
Exac. Type
|
Days
|
MMRM
Least Square Means |
P-Value*
|
|
AAT
N=73 |
Placebo
N=71 |
||||
Dyspnea
|
0-10
|
11.9464
|
12.2548
|
0.0243
|
|
0-14
|
11.5803
|
11.7832
|
0.0817
|
||
Sputum
Volume |
0-10
|
1.2748
|
1.3837
|
0.0334
|
|
0-14
|
1.2367
|
1.3206
|
0.0595
|
||
Sputum Color
|
0-10
|
2.1566
|
2.0137
|
0.0502
|
|
0-14
|
2.0240
|
1.8393
|
0.0032
|
$MM
|
FY2009
|
FY2010
|
FY2011
|
FY2012
|
FY2013
|
FY2014
|
Proprietary
Products |
10
|
23
|
35
|
47
|
51
|
44
|
Growth
|
|
130%
|
54%
|
32%
|
9%
|
(14%)
|
Distribution
|
4
|
11
|
24
|
26
|
20
|
27
|
Growth
|
|
187%
|
110%
|
8%
|
(23%)
|
35%
|
Total Revenues
|
14
|
34
|
59
|
73
|
71
|
71
|
Growth
|
|
146%
|
73%
|
22%
|
(3%)
|
0%
|
Gross Profit
|
(3)
|
6
|
17
|
23
|
26
|
16
|
R&D
|
(9)
|
(9)
|
(12)
|
(12)
|
(13)
|
(16)
|
S&M and G&A
|
(5)
|
(7)
|
(7)
|
(7)
|
(10) (2)
|
(10)
|
Net Profit
(Loss) |
(21)
|
(14)
|
(4)
|
0.3
|
0.4
|
(11)
|
Adjusted
EBITDA (1) |
(12)
|
(6)
|
1
|
9
|
9
|
(5)
|
U.S. FDA approval for Glassia®
|
|
Strategic agreement with Baxalta & First Glassia® sale in the
U.S. |
|
Strategic agreement for Rabies in the U.S. with Kedrion
|
|
Anti-Snake Venom launch
|
|
Strategic agreement with Chiesi for Inhaled AAT for AATD in
EU |
|
Newly diagnosed type-1 diabetes Phase II trial completed
|
|
Initiation of Phase II/III for type-1 diabetes
|
|
Initiation of U.S. Phase II for Inhaled AAT for AATD
|
|
Initiation of U.S. Phase I/II study of Glassia in GVHD
|
|
Completion of EU Phase II/III Inhaled AAT for AATD trial
|
|
Completion of U.S. Phase III Rabies Ig
|
|
U.S. & EU Orphan Drug Designation for Glassia to treat
GVHD |
|
Increased sales, profitability and production capacity
|
Phase III Rabies Ig trial (U.S.) results
|
2H15
|
Interim data from GVHD trial
|
2H15
|
MAA submission for Inhaled AAT for AATD
|
2H15
|
Completion of Phase II for Inhaled AAT for AATD
trial (U.S.) |
2H15
|
Strategic agreements
|
2015
|
Initiation of Phase II lung transplantation trial
|
2015
|
BLA submission for the Rabies lg in the U.S.
|
2016
|
Initiation of Phase lll for intrevenous AAT for GVHD
|
2016
|
Interim report for Phase II/III for type-1 diabetes trial
|
2016
|
Rabies product launch in the U.S. (if approved)
|
2016/7
|
Inhaled AAT for AATD launch (EU) (if approved)
|
2016/7
|
Reaching $100 million of annual revenues
|
2017
|
Double the number of Glassia patients WW
|
2018
|
Major Three (3) Exacerbation Symptoms by Severity:
Dyspnea; Sputum Volume; Sputum Color
|
||||
Exacerbation
Type/Category
|
Classification Rules
|
Possible Manifestations
|
||
Dyspnea*
|
Sputum
Volume ** |
Sputum
Color** |
||
Type I
|
All 3 symptoms at high score
|
+
|
+
|
+
|
Type II
|
Two of the 3 symptoms at high
score |
+
|
+
|
|
+
|
|
+
|
||
|
+
|
+
|
||
Type III
|
One of the 3 symptoms at high
score |
+
|
|
|
|
+
|
|
||
|
|
+
|
S<_XUYIX
M.6SGMKRWOR5,`!X.,<@'\.17HWA.2TM+Z&6V?Y)P;>49R-XY!'L>:Y:T8RHV
M6YT1J2C7L]KGH8IX%,%2"O)9ZJ'"GBF"G`U#*,_Q!.]MX=U*>,X>.UD93Z$*
M<5\;WLKR7,K.Q)+$DFOL/Q2-WA/5Q_TYR_\`H)KX[NEQ,X/.":K[`X?&5?QH
MQ2D#(H`&>_M65C<I
MZSHMQYD2AECQVP@%;;11R*0R*1]*YC1,J@KIT;*UQ5%J=,=CA_&.D1"(R1Q@
M#%>074'D:@C`$8;/%>_Z_%YUHP]NAKQC7+39H(P:\>U3X)/)<2/8WL)C))`E!!'Y54;.+5PO:5
MSP0@G'%*%<]`:Z;4M*ETJX>&YLY8V1L$M&0/UJ"2&6"$S/9S+%_>*<4.DT4J
MJ9G643?Q+CWKH;-0N*R%U*).B$&I4UC'W5H5D#N=M8O&K#)`KLM'O;2/;N?'
M%>1QZW*<;8U_[Z`JS'K%[G"1@?\`;0"KNB+,^C]+UBP1%S.@K?36]/VC%S'^
M=?+R:OJ1`VXSCD&51C]:>FLZFY`VGGIB45E*DI=2U-KH?2M[J-G/"P6YC/IS
M7FGB&&-Y696!'M7G0U74LKF.3D_WZ]1TKX=7=Y:6US=ZKM26-9&C122,C.,D
MUI&"IJ[9G*?,[(ZOP$V?#,8])&'ZUU&:HZ=I]OI=C':6J[8HQ@9.2?4FJFL^
M([#1(2]S*#)_#$IRQK%IU)^ZA\T81]YE_4=0M],LI+JYD"1Q@DDUXEK&M2:_
MJTMQ(<1GA1_=3L*MZSK6H^*KH,VZ*T0_+&.G_P!U4[@6NC8_UA'_;P/\`"D,&AK]Z;_R8_P#K5QB^&]3(_P!2
M_P"='_",:FW_`"Q;\30ZM3^0%AX?\_#K'.@HW^NS_P!O'_UJBDN]!3D,#CUG
M8US(\)ZD?^6>/QIP\)WW<#\32]K6_D'["EUJ,W7UG08SS&"/9VJ)_$N@QCY+
M&61NWSD"LQ?"=T<;G4?C3U\)$??DI.>(>R*4,,MY-D=QXA65CY$"PJ3P-Q/\
MZH37ES/QO89_&MF/PS`G)R?PJ<:/'']U:3C7E\3+C4H0^&)SL<3LV&.3ZXJ]
M"LD;`YP/>M&6%+<9=DC'JS!1^M4GN[-?^7N#_OZO^-3R*F]65[6=1:1T/3OA
MWXG:.0:7=.2C']T2>A]*]2!]Z^9+/5K2VN%D6\A4J00?,%>S:+\1?#D^E0-=
MZS:17`7#JTG.:Y\0HOWTSJPJG%6II:F%J0M5*(N8<6IN:86II:J2(;'$TTG%-+4TM5)$-BEJ86IK-32U6D0V*
M6IA:D+4PM5I&;8I:F,U(S4PM5I$-BEL4PM32U-)JTC-L":C8T$TPM5I$-@34
M;&AFYJ-C6B1E)B,:86H)II/%49-B$TQFH9JB9JM(ELL)RJ_2GU'&WR#Z4\&O
M./H42"G`5&&IX.:10\4X4T&G`\4@0\4X4BFG5):0X5D>*=5_LC09YP<2-\D?
MU/\`DUL"O,?BCJ):ZMK!#Q&GF-]3_P#6'ZU,Y
X26"RC#0!
MA[KFJRZ+"@PED@[\1BLJM13L;TX.&AXTL9#J1U[YI8T8S[NQ/6O7)=&4_P#+
MLG_?(JC+H\2C_4QKCV%8NSZFJ;70YK0U_P!-A)!P&S^%;T]WN)Q@